| Disease Specific Interactions between Host Protein and DME (HOSPPI) |
| ICD Disease Classification Healthy |
| ICD-11: Healthy |
Click to Show/Hide the Full List of HOSPPI: 2 HOSPPI
|
| Oligomerization |
| Epoxide hydrolase 1 (EPHX1) |
Health |
Heterooligomer |
| Uniprot ID |
|
| Interaction Name |
EPHX1, UGT1A1 and CYP1A1 heterooligomerization |
[1] |
| Studied Cell Lines |
liver microsomes |
| Description |
Epoxide hydrolase 1 (EPHX1) and UDPGT 1-1 (UGT1A1) are reported to heterooligomerize with the CYP1A1 protein, which leads to an increased activity of the drug-metabolizing enzyme Cytochrome P450 1A1. As a result, the interaction among EPHX1, UGT1A1 and CYP1A1 can facilitate the drug-metabolizing process of Cytochrome P450 1A1. |
| UDPGT 1-1 (UGT1A1) |
Health |
Heterooligomer |
| Uniprot ID |
|
| Interaction Name |
UGT1A1, EPHX1 and CYP1A1 heterooligomerization |
[1] |
| Studied Cell Lines |
liver microsomes |
| Description |
UDPGT 1-1 (UGT1A1) and Epoxide hydrolase 1 (EPHX1) are reported to heterooligomerize with the CYP1A1 protein, which leads to an increased activity of the drug-metabolizing enzyme Cytochrome P450 1A1. As a result, the interaction among UGT1A1, EPHX1and CYP1A1 can facilitate the drug-metabolizing process of Cytochrome P450 1A1. |
| ICD Disease Classification 02 Neoplasms |
| ICD-11: 2B90 Colorectal cancer |
Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI
|
| Transcription-factor regulation |
| PPA receptor alpha (PPARA) |
Colorectal cancer |
Activation |
| Uniprot ID |
|
| Interaction Name |
PPARA-CYP1A1 interaction |
[2] |
| Studied Cell Lines |
Caco-2 cell line |
| Ensembl ID |
|
| Description |
PPA receptor alpha (PPARA) is reported to activate the transcription of CYP1A1 gene, which leads to an increased expression of the drug-metabolizing enzyme Cytochrome P450 1A1. As a result, the interaction between PPARA and CYP1A1 can activate the drug-metabolizing process of Cytochrome P450 1A1. |
| ICD-11: 2C12 Liver cancer |
Click to Show/Hide the Full List of HOSPPI: 4 HOSPPI
|
| Transcription-factor regulation |
| Aryl hydrocarbon receptor (AHR) |
Liver cancer |
Repression |
| Uniprot ID |
|
| Interaction Name |
AHR-CYP1A1 interaction |
[3], [4], [5] |
| Studied Cell Lines |
HepG2 and Hepa-1c1c7 cell lines |
| Ensembl ID |
|
| Description |
Aryl hydrocarbon receptor (AHR) is reported to repress the transcription of CYP1A1 gene, which leads to a decreased expression of the drug-metabolizing enzyme Cytochrome P450 1A1. As a result, the interaction between AHR and CYP1A1 can repress the drug-metabolizing process of Cytochrome P450 1A1. |
| Hypoxia-inducible factor 1-beta (ARNT) |
Liver cancer |
Activation |
| Uniprot ID |
|
| Interaction Name |
ARNT-CYP1A1 interaction |
[6] |
| Studied Cell Lines |
HuH7 and HepG2 cell lines |
| Ensembl ID |
|
| Description |
Hypoxia-inducible factor 1-beta (ARNT) is reported to activate the transcription of CYP1A1 gene, which leads to an increased expression of the drug-metabolizing enzyme Cytochrome P450 1A1. As a result, the interaction between ARNT and CYP1A1 can activate the drug-metabolizing process of Cytochrome P450 1A1. |
| Nuclear factor 1 C-type (NFIC) |
Liver cancer |
Repression |
| Uniprot ID |
|
| Interaction Name |
NFIC-CYP1A1 interaction |
[7] |
| Studied Cell Lines |
HepG2 cell line |
| Ensembl ID |
|
| Description |
Nuclear factor 1 C-type (NFIC) is reported to repress the transcription of CYP1A1 gene, which leads to a decreased expression of the drug-metabolizing enzyme Cytochrome P450 1A1. As a result, the interaction between NFIC and CYP1A1 can repress the drug-metabolizing process of Cytochrome P450 1A1. |
| Upstream stimulatory 1 (USF1) |
Liver cancer |
Repression |
| Uniprot ID |
|
| Interaction Name |
USF1-CYP1A1 interaction |
[8] |
| Studied Cell Lines |
Human liver cancer cell line (HepG2) and mouse hepatoma Hepa-1c1c7 cell line |
| Ensembl ID |
|
| Description |
Upstream stimulatory 1 (USF1) is reported to repress the transcription of CYP1A1 gene, which leads to a decreased expression of the drug-metabolizing enzyme Cytochrome P450 1A1. As a result, the interaction between USF1 and CYP1A1 can repress the drug-metabolizing process of Cytochrome P450 1A1. |
| ICD-11: 2C25 Lung cancer |
Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI
|
| DNA methylation |
| DNA methyltransferase (DNMT) |
Lung cancer |
Significant hypomethylation |
| Uniprot ID |
|
| Interaction Name |
DNMT-CYP1A1 interaction |
[9] |
| Studied Cell Lines |
Lung tissue |
| Description |
DNA methyltransferase (DNMT) is reported to significantly hypo-methylate the CYP1A1 gene, which leads to a significantly increased expression of the drug-metabolizing enzyme Cytochrome P450 1A1. As a result, the interaction between DNMT and CYP1A1 can significantly affect the drug-metabolizing process of Cytochrome P450 1A1. |
| ICD-11: 2C60 Breast cancer |
Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI
|
| Transcription-factor regulation |
| Estrogen receptor (ESR1) |
Breast cancer |
Repression |
| Uniprot ID |
|
| Interaction Name |
ESR1-CYP1A1 interaction |
[10] |
| Studied Cell Lines |
MCF-7 cell line |
| Ensembl ID |
|
| Description |
Estrogen receptor (ESR1) is reported to repress the transcription of CYP1A1 gene, which leads to a decreased expression of the drug-metabolizing enzyme Cytochrome P450 1A1. As a result, the interaction between ESR1 and CYP1A1 can repress the drug-metabolizing process of Cytochrome P450 1A1. |
| ICD-11: 2C77 Cervical cancer |
Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI
|
| Histone modification |
| Histone deacetylases (HDACs) |
Cervical cancer |
Repression |
| Uniprot ID |
|
| Interaction Name |
HDACs-CYP1A1 interaction |
[11] |
| Studied Cell Lines |
HeLa cell line |
| Description |
Histone deacetylases (HDACs) are reported to deacetylate the CYP1A1 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Cytochrome P450 1A1. As a result, the interaction between HDACs and CYP1A1 can inhibit the drug-metabolizing process of Cytochrome P450 1A1. |
|
|
|
|
|
|
